

Curriculum Vitae

Name: Atieh Amouzegar

Heading:

Current Address: Full Professor, Head of the Endocrine Research Center, Research Institute for Endocrine Sciences (RIES), Shahid Beheshti University of Medical Sciences. – Iran P.O.Box: 19395-4763

- **Current Phone:** +982122432500
- **Office Phone:** +982122432500
- **Fax:** +982122402463
- **Permanent Address:** Endocrine Research center, Research Institute for endocrine sciences, Shahid Beheshti University of Medical Sciences.– Iran P.O.Box: 19395-4763

Education:

Name of College/University:

- Medical doctor. Iran University of Medical Sciences, Tehran Iran Year of Graduation: 1998
- Specialty of Internal Medicine .Tehran University of medical science, Tehran Iran 2004
- Sub specialty of endocrinology and metabolism Shahid Beheshti University of medical science, Tehran Iran 2007
- **Thesis Title:** “day to day variation in urinary iodine in pregnant women resident of iodine sufficient area”

Honors of Awards:

- Second rank of National Board of Endocrinology in 2007

Relevant Experience:

Organization: Professor, Faculty Member of Research Institute for endocrine sciences, Shahid Beheshti University of Medical Sciences Tehran Iran

Employed/Worked: 2007

Title: Full Professor

Description of Duties: Education and Research

Professional Associations:

Name: Organization: Iranian Endocrine Society-Tehran-Iran 2003

Positions Held: Membership: Member of Executive Committee

Name: Research Committee of Research Institute for Endocrine Sciences, Shahid Beheshti University of medical sciences 2007

Positions Held: Membership

Name: American Association of Clinical Endocrinology (AACE)

Positions Held: member

Name: Endocrine Society

Positions Held: member

Publications:

2011

1. Azizi F, Amouzegar A. Eur J Endocrinol. Management of hyperthyroidism during pregnancy and lactation. 2011 Jun; 164(6):871-6.
2. Azizi F, Hosseini MS, Amouzegar A, Tohidi M, Ainy E. Neonatal thyroid status in an area of iodine sufficiency. J Endocrinol Invest. 2011 Mar; 34(3):197-200.
3. Ghazi AA, Boustani I, Amouzegar A, Attarian H, Pourafkari M, Gashti HN, Sabetian T, Tirgari F, Ghazi S, Kovacs K. Postpartum hypercalcemia secondary to a neuroendocrine tumor of pancreas; a case report and review of literature. Iran J Med Sci. 2011 Sep; 36(3):217-21.

2012

4. Mehran L, Amouzegar A, Delshad H, Azizi F. Association between serum TSH concentration and body mass index in euthyroid subjects: the role of smoking. Arch Iran Med. 2012 Jul; 15(7):400-3.
5. Delshad H, Amouzegar A, Mirmiran P, Mehran L, Azizi F. Eighteen years of continuously sustained elimination of iodine deficiency in the Islamic Republic of Iran: the vitality of periodic monitoring. Thyroid. 2012 Apr; 22(4):415-21.
6. Mehran L, Amouzegar A, Delshad H, Azizi F. The association of cigarette smoking with serum TSH concentration and thyroperoxidase antibody. Exp Clin Endocrinol Diabetes. 2012 Feb; 120(2):80-3.
7. Azita Zadeh-Vakili, Fahimeh Ramezani Tehrani, Somayeh Hashemi, Atieh Amouzegar, Fereidoun Azizi. Relationship between Sex Hormone Binding Globulin, Thyroid Stimulating Hormone, Prolactin and Serum Androgens with Metabolic Syndrome Parameters in Iranian Women of Reproductive Age. Diabetes Metab 2012; S2-008.
8. Z. Sabet, F. Azizi, A. Amouzegar. Serum testosterone, free testosterone index and SHBG concentration for reduction of metabolic syndrome in Tehranian men. Endocrine Care 2012; VIII: 453-466.

2013

9. Amouzegar A, Azizi F. Hormones (Athens). Variations of urinary iodine during the first trimester of pregnancy in an iodine-replete area. Comparison with non-pregnant women. 2013 Jan-Mar; 12(1):111-8.

10. Fam B, Amouzegar A, Arzhan S, Ghanbariyan A, Delshad M, Hosseinpanah F, Azizi F. Association between Physical Activity and Metabolic Risk Factors in Adolescents: Tehran Lipid and Glucose Study. *Int J Prev Med*. 2013 Sep; 4(9):1011-7.
11. Amouzegar A, Delshad H, Mehran L, Tohidi M, Khafaji F, Azizi F. Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. *J Endocrinol Invest*. 2013 Dec; 36(11):950-4.
12. Mehran L, Amouzegar A, Delshad H, Askari S, Hedayati M, Amirshakari G, Azizi F. Trimester-specific reference ranges for thyroid hormones in Iranian pregnant women. *J Thyroid Res*. 2013; 2013:651517.
13. Azizi F, Amouzegar A, Delshad H, Tohidi M, Mehran L, Mehrabi Y. Natural course of thyroid disease profile in a population in nutrition transition: Tehran Thyroid Study. *Arch Iran Med*. 2013 Jul; 16(7):418-23.
14. Alamdari S, Azizi F, Delshad H, Sarvghadi F, Amouzegar A, Mehran L. Management of hyperthyroidism in pregnancy: comparison of recommendations of american thyroid association and endocrine society. *J Thyroid Res*. 2013; 2013:878467.
15. Mehran L, Tohidi M, Sarvghadi F, Delshad H, Amouzegar A, Soldin OP, Azizi F. Management of thyroid peroxidase antibody euthyroid women in pregnancy: comparison of the American thyroid association and the endocrine society guidelines. *J Thyroid Res*. 2013; 2013:542692.
16. Faam B, Hosseinpanah F, Amouzegar A, Ghanbarian A, Asghari G, Azizi F. Leisure-time physical activity and its association with metabolic risk factors in Iranian adults: Tehran Lipid and Glucose Study, 2005-2008. *Prev Chronic Dis*. 2013; 10:E36.
17. Azizi F, Mehran L, Amouzegar A, Delshad H, Tohidi M, Askari S, Hedayati M. Establishment of the trimester-specific reference range for free thyroxine index. *Thyroid*. 2013 Mar; 23(3):354-9.

2014

18. Amouzegar A, Ainy E, Khazan M, Mehran L, Hedayati M, Azizi F. Local versus international recommended TSH references in the assessment of thyroid function during pregnancy. *Horm Metab Res*. 2014 Mar; 46(3):206-10.
19. Amouzegar A, Khazan M, Hedayati M, Azizi F. An assessment of the iodine status and the correlation between iodine nutrition and thyroid function during pregnancy in an iodine sufficient area. *Eur J Clin Nutr*. 2014 Mar; 68(3):397-400.
20. Azizi F, Amouzegar A, Mehran L, Alamdari S, Subekti I, Vaidya B, Poppe K, Sarvghadi F, Luis Jr TS, Akamizu T. Management of hyperthyroidism during pregnancy in Asia. *Endocr J*. 2014; 61(8):751-8.

21. Azizi F, Amouzegar A, Mehran L, Alamdari S, Subekti I, Vaidya B, Poppe K, Luis Jr TS, Akamizu T. Screening and management of hypothyroidism in pregnancy: Results of an Asian survey. *Endocr J*. 2014; 61(7):697-704.
22. Amouzegar A, Beigy M, Gharibzadeh S, Azizi F. Underestimation of Thyroid Dysfunction Risk Due to Regression Dilution Bias in a Long-Term Follow-Up: Tehran Thyroid Study (TTS). *Horm Metab Res*. 2014 Jun; 46(6):440-4.
23. Khazan M, Amouzegar A, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Prevalence of hypothyroidism in patients with dyslipidemia: Tehran Thyroid Study (TTS). *Horm Metab Res*. 2014 Dec; 46(13):980-4.
24. Delshad H, Amouzegar A, Mehran L, Azizi F. Comparison of two guidelines on management of thyroid nodules and thyroid cancer during pregnancy. *Arch Iran Med*. 2014 Oct; 17(10):670-3.
25. Amouzegar A, Mehran L, Sarvghadi F, Delshad H, Azizi F, Lazarus JH. Comparison of the American Thyroid Association with the Endocrine Society practice guidelines for the screening and treatment of hypothyroidism during pregnancy. *Hormones (Athens)*. 2014 Jul-Sep; 13(3):307-13.
26. Mehran L, Amouzegar A, Tohidi M, Moayedi M, Azizi F. Serum free thyroxine concentration is associated with metabolic syndrome in euthyroid subjects. *Thyroid*. 2014 Nov; 24(11):1566-74.

2015

27. Amouzegar A, Kazemian E, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Association between thyroid hormones, thyroid antibodies and insulin resistance in euthyroid individuals: A population-based cohort. *Diabetes Metab.* 2015 Dec; 41(6):480-8.

2016

28. Azizi F, Mehran L, Amouzegar A, Alamdari S, Subetki I, Saadat N, Moini S, Sarvghadi F. Prevalent Practices of Thyroid Diseases During Pregnancy Among Endocrinologists, Internists and General Practitioners. *Int J Endocrinol Metab*. 2015 Nov 7; 14(1):e29601. doi: 10.5812/ijem.29601. eCollection 2016 Jan.
29. Amouzegar A, Bakhtiyari M, Mansournia MA, Etemadi A, Mehran L, Tohidi M, Azizi F. Sex and age specific reference values and cut-off points for TPOAb: Tehran Thyroid Study (TTS). *Thyroid*. 2016 Mar; 26(3):458-65.
30. Amouzegar A, Heidari M, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. The Association between Blood Pressure and Normal Range Thyroid Function Tests in a Population Based Tehran Thyroid Study. *Horm Metab Res*. 2016 Mar; 48(3):151-6.
31. Malek M, Esfahanian F, Amouzegar A, Sarvghadi F, Moossavi Z, Mohajeri-Tehrani MR, Khamseh ME, Amirbaigloo A, Ebrahim Valojerdi A. A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran. *Med J Islam Repub Iran*. 2016 Feb 21;30:334. eCollection 2016.
32. Ghannadi S, Amouzegar A, Amiri P, Karbalaefar R, Tahmasebinejad Z, Kazempour-Ardebili S. Evaluating the Effect of Knowledge, Attitude, and Practice on Self-Management in Type 2 Diabetic Patients on Dialysis. *J Diabetes Res*. 2016:3730875.
33. Ramezani Tehrani F, Bahri Khomami M, Amouzegar A, Azizi F. Thyroperoxidase antibodies and polycystic ovarian morphology. *Int J Gynaecol Obstet*. 2016 Aug;134(2):197-201
34. Bagheripuor F, Gharibzadeh S, Ghanbari M, Amouzegar A, Tohidi M, Azizi F, Ghasemi A. Association between serum nitric oxide metabolites and thyroid hormones in a general population: Tehran Thyroid Study. *Endocr Res*. 2016 Aug;41(3):193-9.
35. Gharibzadeh S, Mohammad K, Rahimiforushani A, Amouzegar A, Mansournia MA. Standardization as a Tool for Causal Inference in Medical Research. *Arch Iran Med*. 2016 Sep;19(9):666-670.
36. Karbalaefar R, Kazempour-Ardebili S, Amiri P, Ghannadi S, Tahmasebinejad Z, Amouzegar A. Evaluating the effect of knowledge, attitude and practice on self-management in patients with type 2 diabetes. *Acta Diabetol*. 2016 Dec;53(6):1015-1023.
37. Alamdari SH, Amouzegar A, Tohidi M, Gharibzadeh S, Kheirkhah P, Kheirkhah P, Azizi F. Hypothyroidism and Lipid Levels in a Community Based Study (TTS). *International Journal of Endocrinology and Metabolism*. *Int J Endocrinol Metab*. 2016 Jan; 14(1):e22827.

2017

38. Amouzegar A, Mehran L, Hasheminia M, Kheirkhah Rahimabad P, Azizi F. The predictive value of metabolic syndrome for cardiovascular and all-cause mortality: Tehran Lipid and Glucose Study. *Diabetes Metab Res Rev. Diabetes Metab Res Rev.* 2017 Jan; 33(1).
39. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, Khalili D, Hedayati M, Ebrahimi A, Hajsheikholeslami F, Mirmiran P, Ramezani Tehrani F, Momenan AA, Ghanbarian A, Amouzegar A, Amiri P, Azizi F.N. Rationale and Design of a Genetic Study on Cardiometabolic Risk Factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS). *JMIR Res Protoc.* 2017 Feb 23;6(2):e28.
40. Amouzegar A, Gharibzadeh S, Kazemian E, Mehran L, Tohidi M, Azizi F. The Prevalence, Incidence and Natural Course of Positive Antithyroperoxidase Antibodies in a Population-Based Study: Tehran Thyroid Study. *PLoS One.* 2017 Jan 4;12(1):e0169283.
41. Amouzegar A, Ghaemmaghani Z, Beygi M, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Natural course of euthyroidism and clues for early diagnosis of thyroid dysfunctions: Tehran Thyroid Study (TTS). *Thyroid.* 2017 May;27(5):616-625.
42. Amiri P, Hamzavi-Zarghani N, Nazeri P, Ghofranipour F, Karimi M, Amouzegar A, Azizi F. Can an educational intervention improve iodine nutrition status in pregnant women? A randomized controlled trial. *Thyroid.* 2017 Mar;27(3):418-425.
43. Mehran L, Amouzegar A, Rahimabad PK, Tohidi M, Tahmasebinejad Z, Azizi F. Thyroid Function and Metabolic Syndrome: A Population-Based Thyroid Study. *Horm Metab Res.* 2017 Mar;49(3):192-200.
44. Amiri P, Asghari G, Sadrosadat H, Karimi M, Amouzegar A, Mirmiran P, Azizi F. Nutrients. Psychometric Properties of a Developed Questionnaire to Assess Knowledge, Attitude and Practice Regarding Vitamin D (D-KAP-38). 2017 May 8;9(5). pii: E471.
45. Ahi S, Amouzegar A, Gharibzadeh S, Kazempour-Ardebili S, Delshad H, Tohidi M, Azizi F. The Association Between Normal Range TSH and Lipid Profile. *Horm Metab Res.* 2017 Jun;49(6):424-429. doi: 10.1055/s-0043-110142. Epub 2017 Jun 8.
46. Talaei B, Amouzegar A, Sahranavard S, Hedayati M, Mirmiran P, Azizi F. Effects of Cinnamon Consumption on Glycemic Indicators, Advanced Glycation End Products, and Antioxidant Status in Type 2 Diabetic Patients. *Nutrients.* 2017 Sep 8;9(9). pii: E991.
47. Gholampour Dehaki M, Amouzegar A, Delshad H, Mehrabi Y, Tohidi M, Azizi F. Thyroid dysfunction in patients with impaired glucose metabolism: 11 year follow up from the Tehran Thyroid Study. *PLoS One.* 2017 Oct 3;12(10):e0184808.
48. Mehran L, Amouzegar A, Bakhtiyari M, Mansournia MA, Kheirkhah Rahimabad P, Tohidi M, Azizi F. Variations in serum free thyroxine concentration within normal ranges predict the incidence of metabolic syndrome in non-obese adults: a Cohort Study. *Thyroid.* 2017 Jul;27(7):886-893.

49. Abdi H, Kazemian E, Gharibzadeh S, Amouzegar A, Mehran L, Tohidi M, Rashvandi Z, Azizi F. Association between Thyroid Function and Body Mass Index: A 10-Year Follow-Up. *Ann Nutr Metab.* 2017;70(4):338-345.
50. Abdi H, Hosseinpanah F, Azizi F, Hadaegh F, Amouzegar A. Screening for Dysglycemia: A Comment on Classification and Diagnosis of Diabetes in American Diabetes Association Standards of Medical Care in Diabetes-2016. *Arch Iran Med.* 2017 Jun; 20(6):389.
51. Azizi F, Amouzegar A. Controversies in Management of Hyperthyroidism during Pregnancy. *Arch Iran Med.* 2017 Oct; 20(10):657-658.
52. Mehran L, Khalili D, Yarahmadi S, Amouzegar A, Mojarad M, Ajang N, Azizi F. Worldwide Recall Rate in Newborn Screening Programs for Congenital Hypothyroidism.. *Int J Endocrinol Metab.* 2017 Jun 25;15(3):e55451.
53. Askari S, Abdi H, Ahmadi S, Bahadoran Z, Amouzegar A. Knowledge of Thyroid Disorders during Pregnancy among General Practitioners in Iran. *Int J Endocrinol Metab.* 2017 Jun 21;15(3):e55450.
54. Ghazi AA, Zadeh-Vakili A, Zarif Yeganeh M, Alamdari S, Amouzegar A, Khorsandi AA, Amirbaigloo A, Azizi F. Hereditary Vitamin D Resistant Rickets: Clinical, Laboratory, and Genetic Characteristics of 2 Iranian Siblings. *Int J Endocrinol Metab.* 2017 Jul 31;15(3):e12384.
55. Azizi F, Mehran L, Hosseinpanah F, Delshad H, Amouzegar A. Primordial and Primary Preventions of Thyroid Disease. *Int J Endocrinol Metab.* 2017 Oct 7; 15(4):e57871.
56. Khamseh ME, Mohajeri Tehrani MR, Mousavi Z, Malek M, Imani M, Hoshangian Tehrani N, Ghorbani M, Akbari H, Sarvghadi F, Amouzegar A, Esfahanian F, Hashemi Madani N, Emami Z. Iran Pituitary Tumor Registry: Description of the Program and Initial Results. *Arch Iran Med.* 2017 Dec 31;20(12):746-751.

2018

57. Tohidi M, Derakhshan A, Akbarpour S, Amouzegar A, Mehran L, Baghbani-Oskouei A, Azizi F, Hadaegh F. Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study. *Horm Metab Res*. 2018 Jan;50(1)
58. Azizi F, Amouzegar A. Management of thyrotoxicosis in children and adolescents: 35 years' experience in 304 patients. *J Pediatr Endocrinol Metab*. 2018 Jan 26;31(2):159-165.
59. Abdi H, Gharibzadeh S, Tasdighi E, Amouzegar A, Mehran L, Tohidi M, Azizi F. Associations Between Thyroid and Blood Pressure in Euthyroid Adults: A 9-Year Longitudinal Study. *Horm Metab Res*. 2018 Mar;50(3):236-241.
60. Amouzegar A, Kazemian E, Abdi H, Mansournia MA, Bakhtiyari M, Hosseini MS, Azizi F. Association Between Thyroid Function and Development of Different Obesity Phenotypes in Euthyroid Adults: A Nine-Year Follow-Up.. *Thyroid*. 2018 Apr;28(4):458-464.
61. Abdi H, Azizi F, Amouzegar A. Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review. *Int J Endocrinol Metab*. 2018 Apr 21;16(2):e65600.
62. Azizi F, Mehran L, Hosseinpanah F, Delshad H, Amouzegar A. A Secondary and tertiary preventions of thyroid disease. *Endocr Res*. 2018 May;43(2):124-140.
63. Abdi H, Amouzegar A, Tohidi M, Azizi F, Hadaegh F. Blood Pressure and Hypertension: Findings from 20 Years of the Tehran Lipid and Glucose Study (TLGS). *Int J Endocrinol Metab*. 2018 Oct 20 ;16(4 Suppl):e84769.
64. Parizadeh D, Momenan AA, Amouzegar A, Azizi F, Hadaegh F. Tobacco Smoking: Findings from 20 Years of the Tehran Lipid and Glucose Study. *Int J Endocrinol Metab*. 2018 Oct 31;16(4 Suppl):e84738.
65. Amouzegar A, Mehran L, Takyar M, Abdi H, Azizi F. Tehran Thyroid Study (TTS). *Int J Endocrinol Metab*. 2018 Oct 24; 16(4 Suppl):e84727.
66. Amiri P, Kazemian E, Mansouri-Tehrani MM, Khalili A, Amouzegar A. Does motivational interviewing improve the weight management process in adolescents? Protocol for a systematic review and meta-analysis. *Syst Rev*. 2018 Oct 30; 7(1):178.
67. Sadaie MR, Farhodi M, Zamanlu M, Aghamohammadzadeh N, Amouzegar A, Rosenbaum RE, Thomas GA. What does the research say about androgen use and cerebrovascular events? *Ther Adv Drug Saf*. 2018 May 8;9(8):439-455.
68. Gharibzadeh S, Mansournia MA, Rahimiforoushani A, Alizadeh A, Amouzegar A, Mehrabani-Zeinabad K, Mohammad K. Comparing different propensity score estimation methods for estimating the marginal causal effect through standardization to propensity scores. *Communications in Statistics: Simulation and Computation*. 2018; 47(4): 964-976.

69. Nodehi M, Ajami A, Izad M, Asgarian Omran H, Chahardoli R, Amouzegar A, Yekaninejad S, Hemmatabadi M, Azizi F, Esfahanian F, Mansouri F, Mazaheri Nezhad Fard R, Saboor-Yaraghi AA. Effects of vitamin D supplements on frequency of CD4+ T-cell subsets in women with Hashimoto's thyroiditis: a double-blind placebo-controlled study. *Eur J Clin Nutr*. 2019 Jan 29. doi: 10.1038/s41430-019-0395-z.
70. Mehran L, Khalili D, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study. *Arch Dis Child Fetal Neonatal Ed*. 2019 Mar;104(2):F176-F181. doi: 10.1136/archdischild-2017-313720.
71. Azizi F, Takyar M, Madreseh E, Amouzegar A. Treatment of Toxic Multinodular Goiter: Comparison of Radioiodine and Long-Term Methimazole Treatment. *Thyroid*. 2019 May;29(5):625-630.
72. Azizi F, Takyar M, Madreseh E, Amouzegar A. Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial. *Pediatrics*. 2019 May;143(5). pii: e20183034.
73. Chahardoli R, Saboor-Yaraghi AA, Amouzegar A, Khalili D, Vakili AZ, Azizi F. Can Supplementation with Vitamin D Modify Thyroid Autoantibodies (Anti-TPO Ab, Anti-Tg Ab) and Thyroid Profile (T3, T4, TSH) in Hashimoto's Thyroiditis? A Double Blind, Randomized Clinical Trial. *Horm Metab Res*. 2019 May;51(5):296-301.
74. Ahi S, Amouzegar A, Gharibzadeh S, Delshad H, Tohidi M, Azizi F. Trend of lipid and thyroid function tests in adults without overt thyroid diseases: A cohort from Tehran thyroid study. *PLoS One*. 2019 May 16;14(5):e0216389.
75. Kazemian E, Akbari ME, Moradi N, Gharibzadeh S, Mondul AM, Jamshidi-Naeini Y, Khademolmele M, Zarins KR, Ghodoosi N, Amouzegar A, Davoodi SH, Rozek LS. Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial. *Nutrients*. 2019 Jun 4;11(6). pii: E1264.
76. Keyhanian M, Sarvghadi F, Mehran L, Amouzegar A, Beigy M, Tohidi M, Azizi F. Long-Term Variations of Antithyroperoxidase Antibodies and its Clinical Significance. *Horm Metab Res*. 2019 Jun;51(6):347-352.
77. Mehran L, Yarahmadi S, Khalili D, Hedayati M, Amouzegar A, Mousapour P, Ajang N, Azizi F. Audit of the Congenital Hypothyroidism Screening Program in 15 Provinces of Iran. *Arch Iran Med*. 2019 Jun 1;22(6):310-317
78. Amiri P, Mohammadzadeh-Naziri K, Abbasi B, Cheraghi L, Jalali-Farahani S, Momenan AA, Amouzegar A, Hadaegh F, Azizi F. Smoking habits and incidence of cardiovascular diseases

- in men and women: findings of a 12 year follow up among an urban Eastern-Mediterranean population. *BMC Public Health*. 2019 Aug 5;19(1):1042. doi: 10.1186/s12889-019-7390-0.
79. Kazemian E, Amouzegar A, Akbari ME, Moradi N, Gharibzadeh S, Jamshidi-Naeini Y, Khademolmele M, As-Habi A, Davoodi SH. Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. *Lipids Health Dis*. 2019 Aug 9;18(1):161. doi: 10.1186/s12944-019-1100-x.
 80. Azizi F, Amouzegar A, Tohidi M, Hedayati M, Cheraghi L, Mehrabi Y. Systemic Thyroid Hormone Status in Treated Graves' Disease. *Int J Endocrinol Metab*. 2019 Oct 12;17(4):e95385. doi: 10.5812/ijem.95385. eCollection 2019 Oct.
 81. Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, Mehrabi Y, Takyar M. Increased remission rates after long-term methimazole therapy in patients with Graves' disease: Results of a randomized clinical trial. *Thyroid*. 2019 Sep;29(9):1192-1200. doi: 10.1089/thy.2019.0180. Epub 2019 Aug 28.
 82. Azizi F, Hadaegh F, Hosseiniapanah F, Mirmiran P, Amouzegar A, Abdi H, Asghari G, Parizadeh D, Montazeri SA, Lotfaliany M, Takyar F, Khalili D. Metabolic health in the Middle East and north Africa. *Lancet Diabetes Endocrinol*. 2019 Nov;7(11):866-879. doi: 10.1016/S2213-8587(19)30179-2. Epub 2019 Aug 14. Review.
 83. Kazemian E, Amouzegar A, Akbari ME, Moradi N, Gharibzadeh S, Jamshidi-Naeini Y, Khademolmele M, As'habi A, Davoodi SH. Correction to: Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. *Lipids Health Dis*. 2019 Sep 14;18(1):174. doi: 10.1186/s12944-019-1110-8.
 84. Kazemin E, Jamshidi-naeini Y, Akbari MA, Moradi N, Gharibzadeh S, Amouzegar A, Mondul A, Khademolmele M, Ghodoosi N, Zarins KR, Davoodi SH, Rozek L. Interaction Effects of Vitamin D Receptor Polymorphisms and Vitamin D3 Supplementation on Plasma Oxidative Stress and Apoptotic Biomarkers Among Breast Cancer Survivors (P05-027-19). *Curr Dev Nutr*. 2019 Jun; 3(Suppl 1): nzz030.P05-027-19. Published online 2019 Jun 13. doi: 10.1093/cdn/nzz030.P05-027-19.
 85. Bahri S, Ramezani Tehrani F, Amouzgar A, Rahmati M, Tohidi M, Vasheghani V, Azizi F. Overtime trend of thyroid hormones and thyroid autoimmunity and ovarian reserve: A longitudinal population study with a 12-year follow up. *BMC Endocrine Disorders*, 2019; 19(1): 47.
 86. Mehran L, Amouzegar A, Azizi F. Thyroid disease and the metabolic syndrome. *Curr Opin Endocrinol Diabetes Obes*. 2019 Oct;26(5):256-265. doi: 10.1097/MED.0000000000000500.
 87. Abdi H, Amouzegar A, Azizi F. Antithyroid drugs. *Iranian Journal of Pharmaceutical Research*. *Iran J Pharm Res*. 2019 Autumn; 18(Suppl1): 1–12. doi: 10.22037/ijpr.2020.112892.14005

2020

88. Kadkhodazadeh H, Amouzegar A, Mehran L, Gharibzadeh S, Azizi F, Tohidi M. Smoking status and changes in thyroid-stimulating hormone and free thyroxine levels during a decade of follow-up: The Tehran thyroid study. *Caspian J Intern Med*. 2020 Winter;11(1):47-52.
89. Kazemian E, Akbari ME, Moradi N, Gharibzadeh S, Amouzegar A, Jamshidi-Naeini Y, Mondul AM, Khademolmele M, Ghodoosi N, Zarins KR, Shateri Z, Davoodi SH*, Rozek LS. Effect of vitamin D receptor polymorphisms on plasma oxidative stress and apoptotic biomarkers among breast cancer survivors supplemented vitamin D3. 2020; *European journal of cancer prevention*, 29(5): 433-444.
90. Amouzegar A , Kazemian E, Abdi H, Gharibzadeh S, Tohidi T , Azizi F . Abdominal Obesity Phenotypes and Incidence of Thyroid Autoimmunity: A 9-Year Follow-up. *Endocrine Research*.2020; 45(3): 202-209.
91. Azizi F, Amouzegar A, Mehran M, Abdi H . LT4 and slow release T3 combination: Optimum therapy for hypothyroidism? *International Journal of Endocrinology and Metabolism*, 2020; 18(2): e100870.
92. Takyar M, Rahmani M, Amouzegar A, Madreseh E, Tohidi M, Mehran L, Azizi F. Parity and incidence of thyroid autoimmunity a population-based study Tehran thyroid study (TTS).*Thyroid*. 2020 Mar 11. doi: 10.1089/thy.2019.0440.
93. Amouzegar A, Azizi F, Ashrafi V, Ahi Z, Saleh M, Mohaghegh S, Saleh Gargari S. Prevalence of calcium and vitamin D deficiency and their association with fetal-maternal outcomes in a sample of Iranian pregnant women. *Hum Antibodies*. 2020;28(4):305-312.
94. Etemadi A, Amouzegar A, Mehran L, Tohidi M, Azizi F, Moradi K, Delshad H. Isolated Hypothyroxinemia in Iranian Pregnant Women, the Role of Iodine Deficiency: A Population-Based Cross-Sectional Study. *Thyroid*. 2020 Feb;30(2):262-269.
95. Tohidi M, Baghbani-Oskoue A, Amouzegar A, Mehran L, Azizi F, Hadaegh F*. Serum Thyroid Peroxidase Antibody Level and Incident Hypertension in Iranian Men: A Suggestion for the Role of Thyroid Autoimmunity. *Endocr Metab Immune Disord Drug Targets*. 20(10), 2020.1711-1718(8)
96. Zahedi, M, Kazemian, E, Ramezani-Tehrani, F*, Tohidi M, Azizi, F, Khalili D, Rahmati M, Amouzegar A*. Assessment of the simultaneous effect of hypothyroidism and thyroid autoimmunity with gestational diabetes on the incidence of type 2 diabetes. *BMC Endocrine Disorders*. 20(1), 1 October 2020, 150.
97. Hatami H, Mahdavi M, Amouzegar A, Mehran L, Tohidi M, Azizi F*. Association between Thyroid Function and Body Mass Index in Tehran Thyroid Study Population. *Iranian Journal of Endocrinology and Metabolism*. 22(4), 271 – 278.

98. Mehran L, Khalili D, Amouzegar A, Cheraghi L, Yarahmadi S, Azizi F*. Determining the Prognostic Factors of Permanent Congenital Hypothyroidism. Iranian Journal of Endocrinology and Metabolism. 22(2), 101 – 108.
99. Mehrdad S.M., Amouzegar A*. Hyperglycemia Management in Hospitalized Patients: A Narrative Review. Iranian Journal of Endocrinology and Metabolism. 22(3), pp. 230-251.
100. Mehran L , Amouzegar A, Gharibzadeh S, Abdi H , Mansournia MA, Tohidi M, Azizi F . Cumulative effects of thyroid hormones over 10 years and risk of general and abdominal obesity; tehran thyroid study. Horm Metab Res. 2021 May;53(5):335-340.
101. Abdi H, Amouzegar A*. Management of Graves' Hyperthyroidism: More Than a Century of Progression. International Journal of Endocrinology and Metabolism 18,e103943.

2021

102. Azizi F, Abdi H , Cheraghi L, Amouzegar A*. Treatment of subclinical hyperthyroidism in the elderly: Comparison of radioiodine and long-term methimazole treatment. *Thyroid*. 2021 Aug 18. 2021 Apr;31(4):545-551.
103. Amouzegar A, Asgari S, Azizi F, Momenan AA, Bozorgmanesh M, Hadaegh F*. The Role of Metabolic Syndrome and its Components in Incident Fracture: A 15-Year Follow-Up Among the Iranian Population. *J Clin Endocrinol Metab*. 2021 Apr 23;106(5):e1968-e1983.
104. Faam B, Ghaffari MA, Khorsandi LS, Ghadiri AA*, Totonchi M, Amouzegar A, Fanaei SA, Azizi F, Shahbazian HB , Hashemi Tabar M. RAP1GAP Functions as a Tumor Suppressor Gene and Is Regulated by DNA Methylation in Differentiated Thyroid Cancer. *Cytogenet Genome Res*. 2021 Jul 26;1-9.
105. Birjandi B, Ramezani Tehrani F, Amouzegar A*, Tohidi M, Bidhendi Yarandi R, Azizi F. The association between subclinical hypothyroidism and TPOAb positivity with infertility in a population-based study: Tehran thyroid study (TTS). *BMC Endocr Disord*. 2021 May 26;21(1):108.
106. Mahdavi M , Amouzegar A , Mehran L , Madreseh E, Tohidi M, Azizi F*. Investigating the prevalence of primary thyroid dysfunction in obese and overweight individuals: Tehran thyroid study. *BMC Endocr Disord*. 2021 Apr 30;21(1):89.
107. Azizi F, Abdi H*, Amouzegar A*. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial. *BMC Endocr Disord*. 2021 Jan 14;21(1):16.
108. Mehran L · Amouzegar A · Abdi H · Delbari N · Madreseh E · Tohidi M · Mansournia M.A · Azizi F*. Incidence of Thyroid Dysfunction Facing Metabolic Syndrome: A Prospective Comparative Study with 9 Years of Follow-Up. *Eur Thyroid J* 2021;10:390–398.
109. Kazempour-Ardebili S, Amouzegar A, Tohidi M, Amouzegar A*, Azizi F*. Prevalence of Subclinical Hypothyroidism in Chronic Kidney Disease in a Population-based Study: Tehran Thyroid Study. *Int J Endocrinol Metab*. 2021 Mar 17;19(2):e103750.
110. Valizadeh M, Farhad Hosseinpanah F, Ramezani Tehrani F, Abdi H*, Mehran L, Hadaegh F, Amouzegar A, Sarvghadi F, Azizi F and Iranian Endocrine Society Task Force Iranian Endocrine Society. Iranian Endocrine Society Guidelines for Screening, Diagnosis, and Management of Gestational Diabetes Mellitus. *Int J Endocrinol Metab*. 2021 Jan; 19(1): e107906.
111. Azizi F, Amouzegar A, Abdi H* .Efficacy of low-dose methimazole in control of multiple relapses of Graves' hyperthyroidism: a case report. *J Med Case Rep*. 2021 Apr 23;15(1):189.
112. Ghazi AA*, Amouzegar A, Zadeh-Vakili A, Sheikh Rezaei A, Amirbaigloo A, Zarif Yeganeh M, Hashemi H, Azizi F. Clinical and Laboratory Characteristics of a Large Iranian Kindred Afflicted with Von Hippel Lindau Disease. *Int J Endocrinol Metab*. 2021 Mar 16;19(2):e105189.

113. Nodehi M, Ajami A, Izad M, Asgarian Omran H, Esfahanian F, Yekaninejad S, Hemmatabadi M, Amouzegar A, Chahardoli R, Mansouri F, Saboor-Yaraghi A*. The Frequency of CD4+ T Cells in Women with Hashimoto's Thyroiditis. *Int J Endocrinol Metab*. 2021 Sep 19;19(4):e110013.
114. Amouzegar A, Pearce EN, Mehran L, Lazarus L, Takyar M, Azizi F*. TPO antibody in euthyroid pregnant women and cognitive ability in the offspring: a focused review. *J Endocrinol Invest*. 2021 Sep 13.
115. Abdi H, Faam B, Gharibzadeh S, Mehran L, Tohidi M, Azizi F, Amouzegar A*. Determination of age and sex specific TSH and FT4 reference limits in overweight and obese individuals in an iodine-replete region: Tehran Thyroid Study (TTS). *Endocr Res*. 2021 Feb;46(1):37-43.
116. Zahedi M, Hizomi Arani, Rafati M, Amouzegar A*, Hadaegh F*. Persistent hypercalcemia with similar familial Hypocalciuric hypercalcemia features: a case report and literature review. 2021. *BMC Endocrine Disorders*. 21(1),220
117. Kazemian E, Akbari ME, Moradi N, Gharibzadeh S, Amouzegar A, Rozek LS, Mondul A M, Khademolmele M, Zarins K R, Ghodoosi N, Shateri Z, Fallah S, Davoodi H*. Assessment the effect of vitamin D supplementation on plasma vitamin D levels, inflammation, and oxidative stress biomarkers based on vitamin D receptor genetic variation in breast cancer survivors: a protocol for clinical trial. *J Health Popul Nutr*. 2021 Nov 2;40(1):46.
118. Ghazisaeidi B, Sarvghadi F, Ghasemi A, Tohidi M, Azizi F, Amouzegar A*. Association Between Serum Nitric Oxide Level and Changes in Thyroid Function Test in a Population-based Study: Tehran Thyroid Study Participants (TTS). *Int J Endocrinol Metab*. 2021 Mar 28;19(3):e109214.
119. Mehran L, Shafiee Dolat Abadi S, Amouzegar A, Delshad H*, Azizi F. Trimester-Specific Reference Ranges for Free Thyroxine Hormone in Iranian Pregnant Women. *Iranian Journal of endocrinology and metabolism*. 2021, 23(3): 151-159.(farsi)

2022

120. Kazemian E , Ansari S , Davoodi S.H, Patterson W.B , Shakerinava P, Wagner C.L , Amouzegar A*. The Effect of Maternal Vitamin D Supplementation on Vitamin D Status of Exclusively Breast Feeding Mothers and Their Nursing Infants: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *Adv Nutr.* 2022 Mar;13(2):568-585.
121. Amiri P*, Mansouri-Tehrani MM , Khalili-Chelik A , Karimi M, Jalali-Farahani S, Amouzegar A, Kazemian E. Does Motivational Interviewing Improve the Weight Management Process in Adolescents? A Systematic Review and Meta-analysis. *Int J Behav Med.* 2022 Feb;29(1):78-103
122. Faam B , Ghadiri A.A, Ghaffari M.A, Totonchi M, Amouzegar A, Azizi F, Shahbazian H.B, Hashemitabar M, Fanaei S.A, Khorsandi L. CpG Island Methylation of the Rap1Gap Gene in Medullary Thyroid Cancer. *Arch Iran Med.* 2022;25(3): 171-177.
123. F. Azizi, H. Abdi, L. Mehran, A. Amouzegar*. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. *Journal of Endocrinological Investigation.* 2022: 45, 1139–1150.
124. Mehran L, Delbari N, Amouzegar A*, Hasheminia M, Tohidi M, Azizi F. Reduced sensitivity to thyroid hormone is associated with diabetes and hypertension. *J Clin Endocrinol Metab.* 2022 Jan 1;107(1):167-176.
125. Kazemian E, Davoodi S.H , Akbari M, Moradi N, Gharibzadeh S, Mondul A.M, Jamshidi-Naeini Y, Khademolmele M, Zarins K.R, Ghodoosi N, Rozek L.S*, Amouzegar A*. Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors. *Nutr Cancer.* 2022;74(1):68-81.
126. Mehran L, Amouzegar A*, Fanaei S.M, Masoumi S, Azizi F. Anthropometric measures and risk of all-cause and cardiovascular mortality: An 18 years follow-up. *Obes Res Clin Pract.* Jan-Feb 2022;16(1):63-71.
127. Heba Alwan , Fanny Villos , Martin Feller , Robin P F Dullaart , Stephan J L Bakker , Robin P Peeters , Maryam Kavousi , Douglas C Bauer , Anne R Cappola , Bu B Yeap , John P Walsh , Suzanne J Brown , Graziano Ceresini , Luigi Ferrucci , Jacobijn Gussekloo , Stella Trompet , Massimo Iacoviello , Jae Hoon Moon , Salman Razvi , Isabela M Bensenor , Fereidoun Azizi , Atieh Amouzegar , Sergio Valdés , Natalia Colomo , Nick J Wareham , J Wouter Jukema , Rudi G J Westendorp , Ki Woong Kim , Nicolas Rodondi , Cinzia Del Giovane. Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies. *Eur J Endocrinol.* 2022 Sep 30;187(5):S35-S46.
128. Fereidoun Azizi, Navid Saadat, Mir Alireza Takyar, Hengameh Abdi, Ladan Mehran, Atieh Amouzegar*. Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in

- the Treatment of Toxic Multinodular Goiter. *Endocrinol Metab (Seoul)* 2022 Dec; 37(6): 861–869.
129. Ladan Mehran, Pouria Mousapour, Davood Khalili, Leila Cheraghi, Mohammadjavad Honarvar, Atieh Amouzegar*, Fereidoun Azizi. BMI variability and incident diabetes mellitus, Tehran Lipid and Glucose Study (TLGS). *Sci Rep.* 2022; 12: 18370. Published online 2022 Nov 1.
 130. Fereidoun Azizi , Navid Saadat , Hengameh Abdi *, Ladan Mehran , Safdar Masoumi , Mir Alireza Takyar, Atieh Amouzegar*. Time to Normalization and Sustainable Normal Serum Thyrotropin Concentrations in Patients with Hyperthyroidism: Comparison of Methimazole and Radioactive Iodine Treatments. *Endocrine Practice.* Volume 28, Issue 11, November 2022, Pages 1140-1145.
 131. Majid Valizadeh , Amir Ebadinejad , Atieh Amouzegar , Anahita Zakeri* . Persistent hyperparathyroidism secondary to ectopic parathyroid adenoma in lung: Case report. *Front Endocrinol (Lausanne).* 2022 Dec 13;13:988035.
 132. Amouzegar A, Dehghani M, Abdi H, Mehran L, Masoumi S, Azizi F*. Natural history of subclinical hypothyroidism and prognostic factors for the development of overt hypothyroidism: Tehran Thyroid Study (TTS). *J Endocrinol Invest.* 2022 Dec;45(12):2353-2364.
 133. Azam Erfanifar ,Tayebe yousefzad* ,Homeira Rashidi ,Atieh Amouzegar ,Mohammad Hossein Sarmast Shushtari ,Seyad Ahmad fanaei ,Neptune Emadmootofi ,Fereidoun Azizi ,Saeed Kalbasi. Evaluation of the FNA Accuracy in Differentiating Malignant from Non- Malignant Thyroid Nodules in Comparison with Postoperative Histopathological Findings *Student Research in Translational Medicine*, Vol. 4 (2022), 28 November 2022
 134. N Saadat , F Azizi , H Abdi , A Amouzegar*. Treatment of post-radioactive iodine relapse of hyperthyroidism: comparison of long-term methimazole and radioactive iodine treatment. *J Endocrinol Invest.* 2022 Oct;45(10):1919-1924.(

135. Azizi F, Abdi H, Amouzegar A, Habibi Moeini A.S*. Long-term thionamide antithyroid treatment of Graves' disease. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2023 Mar;37(2):101631.
136. Atieh Amouzegar, Mohammadjavad Honarvar, Safdar Masoumi, Maryam Tohidi, Ladan Mehran*, Fereidoun Azizi. Sex-specific Trajectories of Insulin Resistance Markers and Reduced Renal Function During 18 Years of Follow-up: TLGS. *The Journal of Clinical Endocrinology & Metabolism*, Volume 108, Issue 6, June 2023, Pages e230–e239.
137. Ladan Mehran, Atieh Amouzegar, Seyed Mohsen Foroutan, Safdar Masoumi, Maryam Tohidi, Hengameh Abdi, Ali Aghaei, Amir Esmaeel Saghafeina, Fereidoun Azizi*. Pharmacodynamic and pharmacokinetic properties of the combined preparation of levothyroxine plus sustained-release liothyronine; a randomized controlled clinical trial. *BMC Endocr Disord*. 2023; 23: 182. Published online 2023 Aug 28
138. Mohammadjavad Honarvar, Safdar Masoumi, Ladan Mehran, Davood Khalili, Atieh Amouzegar*, Fereidoun Azizi. Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study. *Sci Rep*. 2023; 13: 7529. Published online 2023 May 9.
139. Behnaz Abiri, Amirhossein Ramezani Ahmadi, Maryam Mahdavi, Farhad Hosseinpanah, Atieh Amouzegar, Majid Valizadeh*. Association between different metabolic phenotypes and the development of hypothyroidism: 9 years follow-up of Tehran thyroid study. *Front Endocrinol (Lausanne)* 2023; 14: 1134983. Published online 2023 Mar 10.
140. Mohammadjavad Honarvar, Ladan Mehran, Safdar Masoumi, Sadaf Agahi, Shayesteh Khalili, Fereidoun Azizi, Atieh Amouzegar*. Independent association between age- and sex-specific metabolic syndrome severity score and cardiovascular disease and mortality. *Scientific Reports* . 2023 Sep 5;13(1):14621
141. Amir Hossein Ghanooni, Azita Zadeh-Vakili, Boshra Rezvankhah, Somayeh Jafari Nodushan, Mahdi Akbarzadeh, Atieh Amouzegar, Maryam S. Daneshpour, Davood Khalili, Yadollah Mehrabi, Seyed Alireza Ebadi, Azizi F*. Longitudinal Associations Between TPO Gene Variants and Thyroid Peroxidase Antibody Seroconversion in a Population-Based Study: Tehran Thyroid Study. *Genet Test Mol Biomarkers*. 2023 Mar;27(3):65-73.
142. Elham Kazemian, Elham Madreseh, Fereidoun Azizi, Sepideh Ashrafiand, Soraya Saleh Gargari, Mohammad Ali Mansournia, Carol L. Wagner, Atieh Amouzegar*. The association of parathyroid hormone with serum 25-hydroxyvitamin during pregnancy. *J Nutr Sci*. 2023; 12: e1
143. Seyedeh Melika Fanaei, Ladan Mehran, Atieh Amouzegar, Safdar Masoumi, Atefeh Amouzegar*, Fereidoun Azizi. The impact of metabolic syndrome on chronic kidney disease development. Insights from a big prospective study. *Eur J Clin Invest*. 2023 Apr;53(4):e13945.

144. Maryam Kabootari, Reza Habibi Tirtashi, Azita Zadeh-Vakili, Maryam Zarkesh, Hossein Samadanifard, Shirin Haghighi, Fereidoun Azizi, Atieh Amouzegar*. RET/PTC rearrangement in papillary thyroid carcinoma arising in malignant struma ovarii with abdominal wall metastasis and cervical thyroid gland: a case report and review of the literature. *Thyroid Res.* 2023 Sep 27;16(1):39.
145. Fereidoun Azizi , Hengameh Abdi , Ladan Mehran , Petros Perros , Safdar Masoumi, Atieh Amouzegar*. Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine. *Endocrine Practice.* 2023 Apr;29(4):240-246.
146. Atieh Amouzegar , Mohammadjavad Honarvar , Safdar Masoumi , Davood Khalili, Fereidoun Azizi , Ladan Mehran* .Trajectory patterns of metabolic syndrome severity score and risk of type 2 diabetes. *J Transl Med.* 2023 Oct 25;21(1):750.
147. Elham Kazemian , Ladan Mehran , Safdar Masoumi , Atieh Amouzegar* , Fereidoun Azizi . Association of trajectory of body shape index with all-cause and cause-specific mortality: 18 years follow-up. *Front Endocrinol (Lausanne).* 2023 Dec 8;14:1259849.
148. Alireza Amirabadizadeh , Atieh Amouzegar , Ladan Mehran , Fereidoun Azizi* .The effect of metformin therapy on serum thyrotropin and free thyroxine concentrations in patients with type 2 diabetes: a meta-analysis. *Sci Rep.* 2023 Oct 31;13(1):18757.
149. Behnaz Abiri , Amirhossein Ramezani Ahmadi , Maryam Mahdavi , Atieh Amouzegar , Majid Valizadeh* . Association between thyroid function and obesity phenotypes in healthy euthyroid individuals: an investigation based on Tehran Thyroid Study. *Eur J Med Res.* 2023 May 30;28(1):179.
150. L Mehran , M Honarvar , S Masoumi , D Khalili , A Amouzegar* , F Azizi. Weight fluctuation, mortality, and cardiovascular disease in adults in 18 years of follow-up: Tehran Lipid and Glucose Study. *J Endocrinol Invest.* 2023 Jan;46(1):37-49.

151. Fereidoun Azizi*, Atieh Amouzegar, Davood Khalili, Hengameh Abdi, Maryam Tohidi, Mehdi Hedayati, Leila Cheraghi, Yadollah Mehrabi, Miralireza Takyar. Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves' hyperthyroidism: a randomized trial and a risk-scoring model. *Endocrine*. 2024 May;84(2):577-588.
152. Azita Zadeh-Vakili Bita Faam, Ali Afgar, Elham Razmpoosh, Maryam Zarkesh*, Atieh Amouzegar*. A systematic review of dysregulated microRNAs in Hashimoto's thyroiditis. *Endocrine*. 2024 Jun;84(3):800-811.
153. Ladan Mehran, Mohammadjavad Honarvar, Safdar Masoumi, Davood Khalili, Fereidoun Azizi, Michael J Blaha*, Atieh Amouzegar*. The association of body mass index variability with cardiovascular disease and mortality: a mediation analysis of pooled cohorts. *Front Endocrinol (Lausanne)*. 2024 May 13;15:1345781.
154. Atieh Amouzegar, Mohammadjavad Honarvar, Safdar Masoumi, Sadaf Agahi, Fereidoun Azizi, Ladan Mehran*. Independent association of metabolic syndrome severity score and risk of diabetes: findings from 18 years of follow-up in the Tehran Lipid and Glucose Study. *BMJ Open*. 2024 Sep 10;14(9):e078701.
155. Siavash Shariatzadeh, Hossein Hatami, Hengameh Abdi, Parisa Amiri, Sepehr Shafiee, Miralireza Takyar, Fereidoun Azizi, Atieh Amouzegar*. Female Reproductive System and Thyroid Dysfunction: Findings from a 12-Year Follow-Up in the Tehran Thyroid Study. *Thyroid*. 2024 Nov;34(11):1424-1434.
156. Fereidoun Azizi*, Ladan Mehran*, Hengameh Abdi, Atieh Amouzegar. Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease. *J Clin Endocrinol Metab*. 2024 Sep 16;109(10):e1881-e1888.
157. Sadaf Agahi, Atieh Amouzegar, Mohammadjavad Honarvar, Fereidoun Azizi, Ladan Mehran*. Interrelationship between thyroid hormones and reduced renal function, a review article. *Thyroid Research*. 2024 Jul 15;17(1):14.
158. Reza Chahardoli, Behrouz Robat-Jazi, Fereidoun Azizi, Atieh Amouzegar, Davood Khalili, Azita Zadeh-Vakili, Fatemeh Mansouri, Ali Akbar Saboor-Yaraghi*. Alterations in CD4+ T Cell Cytokines Profile in Female Patients with Hashimoto's Thyroiditis Following Vitamin D Supplementation: A Double-blind, Randomized Clinical Trial. *Endocr Metab Immune Disord Drug Targets*. 2024;24(12):1454-1463.
159. Nafiseh Hassanloo, Ladan Mehran*, Atieh Amouzegar, Hengameh Abdi*, Safdar Masoumi, Fereidoun Azizi, Seyede Parmis Maroufi. Association between body mass index trajectories and type 2 diabetes incidence over an 18-year follow-up in the Tehran Lipid and Glucose Study. *scientific reports*. 2024 Nov 11;14(1):27615.

160. Shayesteh Khalili , Atieh Amouzegar, Seyed Sattar Dorost , Fereidoun Azizi , Aryan Salahi-Niri . Assessing the predictive value of elevated triglycerides, triglyceride-glucose index (TyG), and TG/HDL ratios for cardiovascular disease and mortality during 20 years of follow-up: Tehran lipid and glucose study. Clin Biochem. 2025 Mar;136:110891.
161. Atoosa Motaghedi Larijani , Safdar Masoumi , Hengameh Abdi , Atieh Amouzegar *, Fereidoun Azizi .The association of thyroid hormone levels and incidence of chronic kidney disease: the Tehran thyroid study (TTS). Thyroid Res. 2025 Apr 2;18(1):13.
162. Alireza Amirabadizadeh, Alireza Ghorbani, Fereidoun Azizi , Hengameh Abdi , Atieh Amouzegar *, Ladan Mehran*. Exploring the bidirectional association between thyrotropin and thyroid hormones in type 2 diabetes: a systematic review and meta-analysis. J Diabetes Metab Disord. 2025 Apr 7;24(1):98.
163. Maryam Adib , Ladan Mehran , Safdar Masoumi , Iman Vatanpoor , Fereidoun Azizi , Atieh Amouzegar*. Optimal Cut-off Points of the Standardized Continuous Metabolic Syndrome Severity Score (cMetS-S) for Predicting Cardiovascular Disease (CVD) and CVD Mortality in the Tehran Lipid and Glucose Study (TLGS). Int J Endocrinol Metab. 2024 Dec 18;22(4):e154255.
164. Maryam Kabootari , Reza Habibi Tirtashi , Atefeh Amouzegar , Safdar Masoumi , Fereidoun Azizi , Atieh Amouzegar*. Changes in metabolic syndrome status and risk of chronic kidney disease over a decade of follow-up in the Iranian population. Sci Rep. 2025 May 30;15(1):19041.
165. F Azizi , A S Moeini , L Mehran , S Masoumi , H Abdi , S M Foroutan , A E Saghafeinia , A Amouzegar*. Treatment of hypothyroidism with the combination of levothyroxine and slow-release triiodothyronine: a randomized clinical trial. J Clin Transl Endocrinol. 2025 Apr 23;40:100395.
166. Fereidoun Azizi, Atieh Amouzegar , Hengameh Abdi , Safdar Masoumi , Ladan Mehran*. Treatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy. Endocr Metab Immune Disord Drug Targets. 2025 Jan 21.
167. F Azizi , A Amouzegar , H Abdi , M Tohidi , S Masoumi , D Khalili , Y Mehrabi , A Zadehvakili , M Hedayati , A A Momenan , L Mehran*. Treatment of hypothyroidism with levothyroxine plus slow-release liothyronine: a study protocol for a randomized controlled double-blinded clinical trial. Trials. 2025 Jul 1; 26(1):228.
168. Alireza Amirabadizadeh, Ladan Mehran, Atieh Amouzegar*, Samaneh Asgari & Fereidoun Azizi*. Evaluating the association between TSH and FT4 levels and the incidence of metabolic syndrome: insights from the Tehran thyroid study using joint modeling. Scientific Reports. 2025 Oct 14;15(1):35835
169. Ladan Mehran , Mohammadjavad Honarvar, Maryam Tohidi, Maryam Adib, Fereidoun Azizi, Atieh Amouzegar*. Association between central thyroid hormone sensitivity and prediabetes: Tehran thyroid study. Front Endocrinol (Lausanne).2025 Jun 17;16:1534058.

170. Maryam Adib , Ladan Mehran , Safdar Masoumi , Fereidoun Azizi , Atieh Amouzegar *. Association between trajectories of waist circumference with incidence of type 2 diabetes mellitus, Tehran lipid and glucose study. Sci Rep. 2026 May 13. doi: 10.1038/s41598-026-51739-w.
171. Azizi F, Abdi H, Ebadi SA, Mehran L, Amouzegar A*. Medical Treatment of Hyperthyroidism; Efficacy and Safety Considerations. Arch Iran Med. 2025 Dec 1;28(12):703-709.
172. Ladan Mehran, Atefeh Amouzegar, Safdar Masoumi, Maryam Adib, Fereidoun Azizi, Atieh Amouzegar*. Trajectory Patterns of Metabolic Syndrome Severity Score and Risk of Chronic Kidney Diseases. Kidney Dis (Basel). 2025 May 28;11(1):530-542.

2026

173. Mohamadamin Tarighat-Payma, Ladan Mehran, Safdar Masoumi, Maryam Tohidi, Atieh Amouzegar*, Fereidoun Azizi*, Elizabeth N Pearce. Long-term natural history of thyroid peroxidase antibodies in a population-based cohort: Findings from 18 years of follow-up in Tehran Thyroid Study (TTS). J Transl Autoimmun. 2026 Feb 16;12:100358.
174. Ladan Mehran, Atieh Amouzegar*, Safdar Masoumi, Mehdi Hedayati, Parvin Mirmiran, Mohamadamin Tarighat-Payma, Golshan Amirshakeri, Fereidoun Aziz*. Beyond Salt Iodization: Sustained Population Sufficiency and Recurrence of Iodine Deficiency in Pregnant Women in Iran. Thyroid. 2026 Mar;36(3):330-339.
175. NCD Risk Factor Collaboration (NCD-RisC). Obesity rise plateaus in developed nations and accelerates in developing nations. Nature. 2026 May;653(8114):510-518.
176. Atieh Amouzegar, Mohamadamin Tarighat-Payma, Safdar Masoumi, Alireza Amirabadizadeh, Hengameh Abdi, Fereidoun Azizi, Ladan Mehran. Thyroid Hormones and Metabolic Syndrome: A Narrative Review of Findings from 18 Years of Follow-up in Tehran Thyroid Study (TTS). International Journal Of Endocrinology And Metabolism. Int J Endocrinol Metab. 2026 Feb 28;24(3):e168079
177. Narges Bagherian , Ladan Mehran, Hengameh Abdi , Safdar Masoumi , Maryam Tohidi , Mohammadjavad Honarvar , Atieh Amouzegar , Fereidoun Azizi. Trends in the incidence and prevalence of thyroid dysfunction over 18 years and projections for 2030: the Tehran thyroid study. J Diabetes Metab Disord. 2026 May 20;25(1):139.
178. Ladan Mehran , Mohamadamin Tarighat-Payma , Safdar Masoumi , Alireza Amirabadizadeh , Fereidoun Azizi , Atieh Amouzegar. Thyroid Hormones and Type 2 Diabetes Mellitus: A Narrative Review of Findings From 18 Years of Follow-up in the Tehran Thyroid Study .Int J Endocrinol Metab. 2026 Apr 29;24(2):e167206.

179. Safdar Masoumi , Mohamadamin Tarighat-Payma , Farhad Shaker , Ladan Mehran , Ramin Assempoor , Fereidoun Azizi , Maryam Adib , Atieh Amouzegar , Davood Khalili .Development and validation of continuous cardiovascular-kidney-metabolic syndrome severity score (cCKMS-S) complementing CKM staging. Lipids Health Dis. 2026 Jun 15;25(1):185.

180.

Epubs

Atieh Amouzegar, Sadaf Agahi, Safdar Masoumi, Mohamadamin Tarighat-Payma, Mohammadjavad Honarvar, Fereidoun Azizi, Ladan Mehran. Dynamic patterns of thyroid hormones and incident chronic kidney disease: evidence from 18 years of follow-up in the Tehran Thyroid Study. J Endocrinol Invest. 2026 Aug 10.

[Hengameh Abdi](#)¹, [Miralireza Takyar](#)¹, [Ladan Mehran](#)¹, [Safdar Masoumi](#)¹, [Atieh Amouzegar](#)¹, [Fereidoun Azizi](#)¹

Sustained Control of Hyperthyroidism in Graves' Disease. Int

J Endocrinol Metab. 2026 Jan 31;24(1):e164940.

Publication in Persian Journals:

2007:

- 1- Amouzegar A, Ordokhani A ,Azizi F. Variation of Urinary Iodine Concentration Within a Month During the First Trimester of Pregnancy in Tehran an Iodine- Repleted Area and Comparison to Non-Pregnant Women. Vol 9 No.1 June 2007. Iranian Journal of Endocrinology & Metabolism

2009:

- 2- Sabet Z, Amouzegar A, Hedayati M, Azizi F. Predicting the Metabolic Syndrome According to Serum Total Testosterone, Free Testosterone Index and SHBG in Males Aged Over 20 Years: Tehran Lipid and Glucose (TLGS). Vol 11, No.4, November 2009. Iranian Journal of Endocrinology & Metabolism.
- 3- A Amouzgar, Y Mehrabi, M Hedayati, P Mirmiran, M Vasei, H Delshad. Goiter and urinary Iodine excretion survey of 8-10 years old school children in Tehran province, 17 years after universal salt iodisation (2007). Pejouhesh dar Pezeshki. 2009, 33(1): 13-20.

2010:

- 4- F Azizi, H Delshad , A Amouzegar, M Hedayati, M Hosseini , M Mehraein .Assessment of Iodine Intake in Yazd province; 17 Years after Universal Salt Iodization (The Fourth National Survey: 2007) .JSSU 2010, 18(3): 263-270.

2011:

- 5- Delshad H, Amouzegar A, Salehi F, Azizkhani N, Delshad M, Azizi F .Goiter and Urinary Iodine Excretion Survey of Schoolchildren in Qazvin Provine: Results of 17 Years Universal Salt Iodization in Iran (2007). Vol 13 No.3 September 2011 .Iranian Journal of Endocrinology & Metabolism.
- 6- Fereidon Azizi , Atieh Amouzegar , Hosein Delshad. Diagnosis and treatment of thyrotoxicosis during pregnancy and lactation. Pajouhandeh. 2011, 15(6): 234-241.
- 7- Hossein Delshad, Atieh Amouzegar, Saeed Sadeghyan Sharif , Ladan Mehran , Farid Ordokhani Feridoun Azizi. Goiter monitoring of schoolchildren in Kermanshah province; 17 years after salt iodization program. Journal of Kermanshah University of Medical Sciences. 2011;15(3)220-226

2012:

- 8- Bahadoran Z , Golzarand M , Mirmiran P , Amouzgar A , Azizi F .Association Between Dietary Phytochemical Index and Occurrence of Metabolic Syndrome and Its Risk Factors (Among Tehranian Adults): Tehran Lipid and Glucose Study. Vol 14 No.4 November 2012 .Iranian Journal of Endocrinology and Metabolism
- 9- Faam B , Amouzegar A , Delshad M , Ghanbarian A , Hossein Panah F , Azizi F. Leisure-Time Physical Activity and its Association with Metabolic Risk Factors in Tehranian Adults: TLGS. Vol 14 No.4 November 2012. Iranian Journal of Endocrinology & Metabolism.

2013:

- 10- Delshad H, Amouzgar A, Mirmiran P, Azizi F .Eighteen Years of Universal Salt Iodization in Iran; The Fourth National Survey of Goiter Prevalence and Urinary Iodine Excretion of Schoolchildren (2007-2008). Vol 15 No.1 May 2013. Iranian Journal of Endocrinology & Metabolism.

- 11- Fam B, Amouzegar A, Arzhan S, Ghanbaryan A, Delshad M, Hosseinpah F, Azizi F. Association between Physical Activity and Metabolic Risk Factors in Adolescents: Tehran Lipid and Glucose Study. Int J Prev Med. 2013 Sep; 4(9):1011-7.
- 12- Azizi F , Delshad H , Amouzegar A , Mehran L , Mirmiran P , Sheikholeslam R, M. Naghavi , A. Ordokhani , M. Hedayati , M Padyab. Marked Reduction in Goiter Prevalence and Eventual Normalization of Urinary Iodine Concentrations in Iranian Schoolchildren, 10 Years After Universal Salt Iodination. Iranian Journal of Endocrinology & Metabolism. 2008, 10(3): 191-203

2014:

- 13- Parisa Amiri, Atieh Amouzegar, Safoora Gharibzadeh, Elham Kazemian, Fahimeh Ramezani Tehrani , Fereidoun Azizi . Socio-behavioral and reproductive determinants associated with contraceptive method choice among Tehranian women: Tehran Lipid and Glucose Study. Pejouhesh dar Pezeshki. 2014, 38(2): 111-119.
- 14- L Mehran, M Delshad, A Amouzegar, Hasheminia M, H Delshad, F Azizi. Does serum TSH Thyrotropin within normal range in associated with body mass index? Iranian Journal of Endocrinology & Metabolism.
- 15- L Mehran, G Amirshakari, A Amouzegar, M Hasheminia, H Delshad, F Azizi. Smoking, thyroid function and thyroxine index antibody. Iranian Journal of Endocrinology & Metabolism.
- 16- Ramezani Tehrani F , Zadeh Vakili A, Hashemi S , Amouzegar A , Azizi F. Associations Between Hormonal Profiles of Urban Iranian Women of Reproductive age: A Community Based Study of Four Provinces. Iranian Journal of Endocrinology & Metabolism. Vol 14 No.1 May 2012.
- 17- Azizi F, Delshad H, Amouzegar A, Mehran L, Mirmiran P, Zahedi Asl S. Prevention of Iodine-deficiency Induced Goiter and Brain Damage in the Islamic Republic of Iran. Iranian Journal of Endocrinology and Metabolism. Vol 15 No.5 January 2014
- 18- Azizi F, Delshad H, Amouzegar A, Mehran L, Mirmiran P, Sheikholeslam R, Naghavi M, Ordokhani A, Hedayati M, Padyab M. Marked Reduction in Goiter Prevalence and Eventual Normalization of Urinary Iodine Concentrations in Iranian Schoolchildren, 10 Years After Universal Salt Iodination (Third National Survey of Iodine Deficiency Disorders 2000)

2015:

- 19- Sadatamini M, Delshad H, Amouzegar A, Tohidi M, Azizi F. The Incidence of Thyroid Dysfunctions in Patients with Type 2 Diabetes: a Twelve-year Follow-up of the Tehran Lipid and Glucose Study. Iranian Journal of Endocrinology and Metabolism. Vol 17 No.1 April-May 2015.

2016:

- 20- HamzaviZarghani N, Ghofranipour F, Amiri P, Amouzegar A, Nazeri P, Hedayati M, Mirmiran P, Azizi F . Iodine Intake Knowledge, Attitude and Practice in Pregnant Women and its Relation to Iodine Status during Pregnancy. Iranian Journal of Endocrinology and Metabolism. Vol 17 No.6 February-March 2016.
- 21- Dr Mahboobeh sadat Hosseini, Dr. Atieh Amouzegar, Dr. maryam tohidi, Zhale Tahmasebinejad , Dr. fereidoun azizi. Prevalence and Incidence of Thyroid Dysfunction in Individuals Aged Over 55 Years (Tehran Thyroid Study). Iranian Journal of Endocrinology and Metabolism. Vol 18 No.3 2016.

22-Clinical guidelines for the diagnosis and treatment of thyroid disorders during pregnancy and postpartum (Iran Endocrine Society). IJEM Vol 18, 3 (serial number 87),Aug –Sep 2016 (FARSI version for Iranian clinicians).

2018:

23- Aidin Baghbani-Oskouei, Samaneh Akbarpour, Maryam Tohidi, Atieh Amouzegar, Ladan Mehran, Farzad Hadaegh, Fereidoun Azizi. Subclinical Thyroid Dysfunction and Incident Cardiovascular Disease: Tehran Thyroid Study. Iranian Journal of Endocrinology and Metabolism. Vol 20 No.1 2018.

2021:

24- L Mehran, S Mahdavi, A Amouzegar, F Azizi Reciprocal association between thyroid function and Metabolic syndrome: A review article. Iranian Journal of Endocrinology and Metabolism. 2021, 23(4): 259-273

25- L Mehran, S Shafiee Dolatabadi, A Amouzegar, H Delshad, F Azizi Trimester-Specific Reference Ranges for Free Thyroxine Hormone in Iranian Pregnant Women. Iranian Journal of Endocrinology and Metabolism. 2021, 23(3): 151-159

2023:

26- M Adib, L Mehran, MJ Honarvar, S Masoumi, F Azizi, A Amouzegar Assessing the risk of cardiovascular diseases: Metabolic syndrome versus quantitative metabolic syndrome severity score. Iranian Journal of Endocrinology and Metabolism. 2023, 25(4): 339-350